Enlivex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K report covers the month of March 2023 for Enlivex Therapeutics Ltd., a company organized under the laws of Israel. The filing serves to furnish the company's audited consolidated financial statements for the years ended December 31, 2022, and 2021, as well as the three-year period ended December 31, 2022.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the audited consolidated financial statements furnished as Exhibit 99.1, which are incorporated by reference into the company's registration statements on Forms S-8, F-3, and F-3MEF.
Material Changes
The filing text does not explicitly detail material changes versus prior periods. It references the inclusion of financial statements for the three-year period ended December 31, 2022, which would contain comparative data, but the specific changes are not summarized in this document.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The document is primarily a procedural filing to deliver audited financial statements to the SEC.
Investor Verification Checklist
- Review Exhibit 99.1 for the actual audited consolidated financial statements and specific financial metrics.
- Verify the incorporation of these statements into registration statements File Nos. 333-256799, 333-232413, 333-232009, 333-252926, and 333-264561.
- Confirm the audit opinion provided by Yarel + Partners (referenced in Exhibit 99.2).
- Check for any subsequent filings that may provide updated operational or financial data beyond the December 31, 2022 period.